ReviewCureus2026
Viscosupplementation in Degenerative Joint Disease: Current Evidence, Indications, and Clinical Outcomes.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra-articular hyaluronic acid (IA-HA), or viscosupplementation, remains a subject of ongoing debate in the non-surgical management of knee osteoarthritis. Despite conflicting clinical guidelines, its use continues to grow due to a favorable safety profile and its role in addressing the "treatment gap" for patients with Kellgren-Lawrence grades II and III. This structured narrative review identifies and synthesizes evidence from PubMed, Scopus, and recent clinical guidelines (2006-2026) to explore the physiological role of IA-HA, emphasizing its rheological properties and the dual mechanism of viscosupplementation and viscoinduction. We evaluate current clinical evidence, acknowledging the inherent heterogeneity of reported outcomes while discussing the potential for symptomatic relief that may, in selected populations, extend beyond the traditional six-month window. Furthermore, this work addresses the social and economic relevance of IA-HA, specifically its opioid-sparing benefits amidst the global opioid crisis and its potential to delay total knee arthroplasty (TKA). By refining patient selection and understanding the impact of molecular weight and combination therapies, clinicians can optimize outcomes. This review provides an evidence-based framework for integrating IA-HA into a multimodal joint preservation strategy to improve quality of life and reduce the global burden of degenerative joint disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.